Expand all sections

Veliparib

Extended indication Non-squamous non-small cell lung cancer (NSCLC), 1L.
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Veliparib
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Lung cancer
Extended indication Non-squamous non-small cell lung cancer (NSCLC), 1L.
Manufacturer Abbvie
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date 2019
Expected Registration 2020
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement

Expected patient volume per year

Patient volume

< 888

Market share is generally not included unless otherwise stated.
References NKR 2016; Pakketadvies Atezolizumab; American Cancer Society
Additional remarks Jaarlijks presenteren er ongeveer 4.500 patiënten per jaar met NSCLC stadium IV. Ongeveer 47% van deze patiënten heeft een niet-plaveiselcelcarcinoom (2.115). Hiervan ontvangt 60% een eerstelijnsbehandeling (1.269) waarvan 70% chemotherapie (888). Hiervan zal een klein deel mogelijk worden behandeld met Veliparib vanwege de behandelopties met immuuntherapie.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.